Piotr Wysocki: Single-agent immunotherapy is a wise choice as first-line treatment in elderly, advanced NSCLC patients, irrespectively of PD-L1 expression
Piotr Wysocki, Professor of Medicine and Head of the Department of Oncology at Jagiellonian University Hospital, shared on LinkedIn:
“Tsukita Y et al. conducted a retrospective analysis of 1245 patients (75 years of age or older) diagnosed with stage IIIB-IV non-small cell lung cancer (NSCLC) who received first-line systemic treatment. PD-L1 expression <1% was detected in 22% of tumors, 1%-49% in 31%, and 50% or higher in 33%, while 14% of cases had unknown PD-L1 status. The authors compared outcomes of patients treated with chemoimmunotherapy, single-agent immunotherapy, platinum-based chemotherapy doublet, and single-agent chemotherapy.
After a median follow-up of 19.2, the median OS was:
- 20.0 months in the chemoimmunotherapy group
- 9.8 months in the single-agent immunotherapy group
- 12.8 months in the platinum-doublet chemotherapy group
- 9.5 months in a single-agent chemotherapy group
The median PFS was:
- 7.7 months in chemoimmunotherapy group
- 7.7 months in single-agent immunotherapy group
- 5.4 months in the platinum-doublet chemotherapy group
- 3.4 months in single-agent chemotherapy group
The analysis demonstrated that in elderly patients, there were no significant differences between single-agent immunotherapy (A) and chemoimmunotherapy (B), regardless of histology or PD-L1 expression:
- Adenocarcinoma – OS: 26.2 months (A) vs 20.4 months (B) – HR, 1.03; 95% CI, 0.78-1.37
- Squamous-cell cancer – OS: 18.3 months (A) vs 13.8 months (B) – HR,0.79; 95%CI,0.57-1.09
- PD-L1 1%-49% – OS: OS: 19.0 months (A) vs 14.5 months (B) – HR, 1.11; 95% CI, 0.65-1.91 PD-L1 >50% – OS: 26.2 months (A) vs 28 months (B) – HR, 0.92; 95% CI, 0.55-1.56
The study of Tsukita Y et al. clearly demonstrates that elderly, fragile, advanced NSCLC patients do not benefit from aggressive systemic treatment based on a combination of chemotherapy and checkpoint inhibitors. Such a population should be offered single-agent immunotherapy.
In my clinical practice in elderly NSCLC patients, I consider using chemoimmunotherapy only in individuals presenting with severe symptoms or imminent visceral crisis in whom I use weekly regimens based on a combination of cisplatin (usually 25 mg/m2) or carboplatin (AUC2) + (metronomic vinorelbine [30-40 mg p.o. bid], or weekly paclitaxel [80 mg/m2], or weekly pemetrexed [175 mg/m2]).”
Source: Piotr Wysocki/LinkedIn
About OncoDaily
OncoDaily was founded in 2023. It is a US-based oncology media platform, that features the latest news, insights, and patient stories from the world of oncology. Within a short period of time, it became one of the leading oncology media platforms globally.
OncoDaily gathers content from various sources, including social media posts from renowned oncologists from all over the world, news from oncology societies and cancer centers, patient and survivor stories, and career-related information for professionals.
The mission of OncoDaily is to empower patients, survivors, and professionals with the knowledge and inspiration they need to fight cancer. The motto of OncoDaily is “Cancer doesn’t take a day off – neither do we”.
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023